Skip to main content
. 2014 Jan 9;143(3):493–505. doi: 10.1007/s10549-013-2828-z

Fig. 2.

Fig. 2

Kaplan–Meier plot: progression-free survival after (a) randomization (intent-to-treat population) and (b) start of crossover treatment (crossover population) QD once daily; PFS progression-free survival; CI confidence intervals; lap lapatinib; cap capecitabine; vin vinorelbine